DBV Technologies S.A. (DBVT) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the DBV Technologies three-year results from the Open Label Extension to Epitope Phase 3 Trial Conference Call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions, To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star then two. Please note, this event is being recorded. I would now like to turn the conference over to Katie Matthews, Investor Relations. Please go ahead. Thank you. This afternoon, DBV Technologies issued a press release announcing year three results from our ongoing open-label extension to the epitope phase three trial, DBV's prior phase three efficacy study, which evaluated vascular peanuts in toddlers ages one to three years old, as well as data from epitopes supporting a potential labeling approach for vascular peanuts. This press release is available in the press releases section of the DBV Technologies website. Before we begin, please note that today's call may include a number of forward-looking statements including but not limited to comments regarding our clinical and regulatory development plans, the design of our anticipated clinical trials, the timing and results of interactions with regulatory agencies, our plans and expectations with respect to our clinical trials, plans with respect to submission of BLAs to FDA, expectations with respect to any actual regulatory pathways, including an accelerated approval pathway, and the ability of any of our product candidates, if approved, to improve the lives of patients with food allergies. These forward-looking statements are based on assumptions th...